IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market revenue to hit USD 36 Billion by 2033, says Research Nester
21 sept. 2023 07h00 HE
|
Research Nester
New York, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The global IBD (Ulcerative Colitis and Crohn's Disease) treatment market is estimated to grow at a CAGR of ~8% over the forecast period. The market is...
Ulcerative Colitis Market Soars to $6.84 Billion in 2023, Registering a 7.7% CAGR - Unlocking Lucrative Investment Opportunities
20 sept. 2023 04h43 HE
|
Research and Markets
Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global ulcerative colitis market is...
Interchangeable Biosimilars Market revenue to hit USD 65 Billion by 2035, says Research Nester
11 sept. 2023 07h00 HE
|
Research Nester
New York, Sept. 11, 2023 (GLOBE NEWSWIRE) -- The global Interchangeable Biosimilars market size is slated to expand at ~ 20 % CAGR between 2023 and 2035. The market is poised to garner a revenue of...
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
29 août 2023 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
03 août 2023 07h05 HE
|
Morphic Therapeutic
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater...
Global Gastrointestinal Partnering Analysis Report 2023: Deal Trends, Players and Financials for Over 480 Deals Signed Since 2016 by the World's Leading Life Science Companies
31 mai 2023 03h13 HE
|
Research and Markets
Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Global Gastrointestinal Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.Global...
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
10 mai 2023 16h05 HE
|
Surrozen, Inc.
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase...
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
10 mai 2023 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
25 avr. 2023 07h00 HE
|
Morphic Therapeutic
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
25 avr. 2023 06h59 HE
|
Morphic Therapeutic
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no...